At a glance

ClinicalIndex Comparison Record

Phase 3Completed

Drug / intervention

duloxetine hydrochloride +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00122824

NCT00122824Phase 3Completed

Duloxetine Hydrochloride 60 mg or 120 mg Once Daily Compared With Placebo in Patients With Generalized Anxiety Disorder.

Eli Lilly and Company·interventional·Posted Jul 22, 2005·Updated Nov 6, 2007

In Brief

A Phase 3 clinical trial evaluating duloxetine hydrochloride and placebo for Anxiety Disorders. Completed, across 7 sites in 7 countries.

This is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesFinland, France, Germany, South Africa, Spain, Sweden, United States

Phase 3CompletedFinished

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJun 2004

First PostedJul 2005

Study CompletionSep 2005

TodayJul 2026

First PostedJul 22, 2005

Enrollment StartJun 1, 2004

Study CompletionSep 1, 2005

TodayJul 2, 2026

Posted 20.9 years ago

duloxetine hydrochloridedrug

placebodrug